Chronicle Journal: Finance

AllPennyStocks.com News: Plant-Based Biopharma Company Jumps to Six-Month High on Clinical Trials for Depression, ADHD

Mississauga, ON -- (SBWIRE) -- 07/28/2020 -- AllPennyStocks.com Media, Inc. (https://www.AllPennyStocks.com/) announces its latest article titled "Plant-Based Biopharma Company Jumps to Six-Month High on Clinical Trials for Depression, ADHD."

Companies mentioned in this article include American BriVision (Holding) Corporation (OTCQB:ABVC), Johnson & Johnson (NYSE:JNJ), Sage Therapeutics (NASDAQ:SAGE), Sanofi (NYSE:SNY) and Bayer (OTC:BAYRY).

Article Excerpt:

People have been using plants as medicine for thousands of years, all the way back to Neanderthal days by some accounts. Innovations such as synthetic chemistry have taken their turn in the spotlight, but with some 300,000 species of plants on Earth, scientists often look back to basics for new drug discoveries. It's called different things in different regions – i.e. Chinese traditional medicine (TCM), "botanical drug" (U.S.), "natural product drug" (Korea), "herbal medicinal product" (Europe) – but, by whatever name, there is an accelerating trend towards plant-based medicine to tackle historically difficult diseases and conditions.

This trend is evidenced by BCC Research forecasting the global market for botanical and plant-derived drugs to grow from $29.4 billion in 2017 to around $39.6 billion by 2022.

The full version of this article can be found at: https://www.allpennystocks.com/specialreportsus/2373/plant-based-biopharma-company-jumps-to-six-month-high-on-clinical-trials-for-depression-adhd

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has been compensated nine thousand dollars by a third-party, Barlew Holdings, LLC. for its efforts in presenting the ABVC profile on its web site and distributing it to its database of subscribers as well as other services. For a complete disclaimer, investors are encouraged to click here: https://www.allpennystocks.com/spotlight/57/american-brivision-holding-corporation.

For more information on this press release visit: http://www.sbwire.com/press-releases/allpennystockscom-news-plant-based-biopharma-company-jumps-to-six-month-high-on-clinical-trials-for-depression-adhd-1298525.htm

Media Relations Contact

Peter Szafranski
Telephone: 1-905-361-5680
Email: Click to Email Peter Szafranski
Web: http://www.allpennystocks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.